16+
Major trials tracked
Immuno-oncology checkpoint inhibitors · Live ClinicalTrials.gov data
Durvalumab (Imfinzi) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 durvalumab trials on ClinicalTrials.gov by enrolment, 2 of them actively recruiting. The next phase 3 primary completion among them is expected Oct 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.
6
Phase 3 trials
2
Actively recruiting
Oct 2026
Next phase 3 primary completion
6,235
Participants across trials
AstraZeneca
Lead sponsor by trial count
durvalumab (16)14 active2014–2030
durvalumab
'14
'16
'18
'20
'22
'24
'26
'28
'30
durvalumab
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckP2
HIMALAYAP3
ADRIATICP3
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneP2
IMMUNO-BILP2
FRAIL-IMMUNEP2
ORCHARDP2
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsP2
TRIPLEXP3
PACIFIC-8P3
Immunological Variables Associated to ICI Toxicity in Cancer PatientsP2
DeLLphi-305P3
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerP3
TREMENDOUS-2P2
SLIDE-HCCP2
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerP2
Upcoming readouts
6 ahead · durvalumab
Select a trial to load its full ClinicalTrials.gov record.
Key durvalumab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05211895 | PACIFIC-8 — A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Parti… | Phase 3 | Recruiting | Jul 2028 |
| NCT03298451 | HIMALAYA — Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinom… | Phase 3 | Active, not recruiting | Aug 2021 |
| NCT03703297 | ADRIATIC — Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patient… | Phase 3 | Active, not recruiting | Jan 2024 |
| NCT06591520 | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | Phase 3 | Active, not recruiting | Oct 2026 |
| NCT06211036 | DeLLphi-305 — Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lun… | Phase 3 | Active, not recruiting | Jul 2027 |
| NCT05223647 | TRIPLEX — Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer | Phase 3 | Terminated | Sept 2025 |
| NCT06880523 | SLIDE-HCC — STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | Phase 2 | Recruiting | Jan 2028 |
| NCT03704480 | IMMUNO-BIL — Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Phase 2 | Active, not recruiting | Jul 2022 |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | Phase 2 | Active, not recruiting | Jan 2023 |
| NCT03660826 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and C… | Phase 2 | Active, not recruiting | Dec 2024 |
| NCT03944772 | ORCHARD — Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertini… | Phase 2 | Active, not recruiting | May 2025 |
| NCT07081633 | TREMENDOUS-2 — Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellul… | Phase 2 | Active, not recruiting | Nov 2026 |
Related drug pipelines
FAQ
- How many clinical trials are running for durvalumab?
- ClinicalTrials.gov lists more than 16 phase 2–4 durvalumab trials. This page tracks the 16 largest by enrolment: 10 phase 2, 6 phase 3, and 0 phase 4 among them, with 2 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare durvalumab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.